Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Oct 14, 2014
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's sNDA for rufinamide and granted it priority review designation as an adjunctive treatment of...
-
Oct 13, 2014
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for BELVIQ® (lorcaserin HCl) CIV will be presented at the American...
- Oct 10, 2014
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that a pooled analysis of the BLOOM and BLOSSOM pivotal, Phase 3 clinical trials of BELVIQ® (lorcaserin HCl) was...
- Oct 1, 2014Findings suggest need for improved education efforts within epilepsy community and beyond to address misperceptions about the disease
Results from a national survey conducted by Eisai Inc., in partnership with the Epilepsy Foundation, found that the vast majority (95%) of epilepsy patients and caregivers believe the public is...
-
Sep 10, 2014
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for BELVIQ® (lorcaserin HCl) CIV will be presented at the American...
